| Names | |
|---|---|
| Preferred IUPAC name | pyridine-3-carboxylic acid |
| Other names | Niacin Vitamin B3 Pyridine-3-carboxylic acid Niaspan |
| Pronunciation | /ˌnɪk.əˈtɪn.ɪk ˈæs.ɪd/ |
| Identifiers | |
| CAS Number | 59-67-6 |
| Beilstein Reference | 0820960 |
| ChEBI | CHEBI:15940 |
| ChEMBL | CHEMBL80 |
| ChemSpider | 876 |
| DrugBank | DB00624 |
| ECHA InfoCard | 100.003.259 |
| EC Number | 3.5.1.19 |
| Gmelin Reference | 7093 |
| KEGG | C00318 |
| MeSH | D009501 |
| PubChem CID | 938 |
| RTECS number | QR6300000 |
| UNII | 9S2TH939TU |
| UN number | 3465 |
| Properties | |
| Chemical formula | C6H5NO2 |
| Molar mass | 123.11 g/mol |
| Appearance | white crystalline powder |
| Odor | Odorless |
| Density | 1.48 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 0.74 |
| Vapor pressure | <0.01 hPa (20°C) |
| Acidity (pKa) | 4.85 |
| Basicity (pKb) | 4.75 |
| Magnetic susceptibility (χ) | -49.0e-6 cm³/mol |
| Refractive index (nD) | 1.515 |
| Viscosity | Viscous liquid |
| Dipole moment | 1.757 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 165.6 J mol⁻¹ K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -322.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3224 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | C10AD02 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P260, P264, P280, P304+P340, P312, P501 |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | 174°C |
| Autoignition temperature | 445°C |
| Lethal dose or concentration | LD50 (oral, rat): 7,500 mg/kg |
| LD50 (median dose) | LD50 (median dose): 7000 mg/kg (oral, rat) |
| NIOSH | RN8757 |
| PEL (Permissible) | PEL: 5 mg/m³ |
| REL (Recommended) | 30 mg |
| IDLH (Immediate danger) | No IDLH Established |
| Related compounds | |
| Related compounds | Nicotinamide Nicotinic acid riboside Nicotinic acid adenine dinucleotide Nicotinic acid mononucleotide Nicotinamide riboside |
| Attribute | Details |
|---|---|
| Product Name | Nicotinic Acid |
| IUPAC Name | Pyridine-3-carboxylic acid |
| Chemical Formula | C6H5NO2 |
| Synonyms & Trade Names | Niacin, 3-Pyridinecarboxylic acid, Vitamin B3 |
| CAS Number | 59-67-6 |
| HS Code & Customs Classification | 2936.26 |
Industrial synthesis of nicotinic acid centers on either the oxidation of 3-methylpyridine or hydrolysis of nicotinonitrile, selected based on raw material availability and waste minimization. Raw material purity remains a main determinant for both process yield and impurity profile in the final product. For niacin, the nature and level of process-related impurities such as pyridine carboxamide or residual pyridine require regular monitoring with HPLC or GC, especially in pharma, food, and feed-grade production. The route and grade affect not only the residual solvent profile but also trace metal content, as certain oxidizing systems introduce specific elemental residues that must be tightly controlled in high-purity applications.
Separation and purification must address reaction by-products and colored impurities, given the sensitivity of many downstream applications. Feed and food grades tolerate broader impurity windows, subject to local and customer-specific limits, while pharmaceutical grades demand multi-stage recrystallization or alternative purification steps as per pharmacopeial monograph. Batch consistency demands constant in-process control of pH, color, and conversion rates.
Storage and handling hinge on moisture control since technical nicotinic acid can absorb water under humid conditions, potentially affecting both handling (caking, flow) and chemical stability. For large-volume lots, packing in hermetic sacks and monitoring warehouse environment minimizes risk.
Customs classification (HS Code 2936.26) covers vitamins and their derivatives. Export and import documentation must accurately correspond to the intended end-use and destination market definitions, as regulatory interpretation of feed or pharma grades can affect required supporting paperwork. Regional regulations may also set unique requirements for additive and residual solvent disclosures, which the manufacturer addresses on a per-shipment basis using certificate of analysis reports backed by validated internal test protocols.
Industrial batches of nicotinic acid present as a crystalline solid, with most grades displaying a white to faintly yellow color depending on impurity profile and drying process. Both technical and pharmaceutical grades are essentially odorless, though slight acetic or pyridine-like off-notes sometimes arise from residual process reagents or container exposure. Typical melting points reported for high-purity grades cluster near 230°C. Boiling is less relevant due to decomposition above this point. Density and morphological properties can shift based on production crystallization kinetics; bulk density changes impact silo transfer, pneumatic conveying, and large-volume blending.
Nicotinic acid remains chemically stable under cool, dry, and light-protected storage. Photo-induced discoloration and degradation can accelerate in transparent or unlined containers. Reactivity concerns focus on compatibility with strong oxidizers and reducing agents that may contact product traces during transfer or downstream use. Stability parameters vary with pH during solution handling; acidic and neutral matrices hold up well, while strong bases increase risk for hydrolysis and byproduct formation.
Aqueous solubility at ambient temperature is moderate and varies with grade, particle size, and batch humidity. Higher-temperature dissolution is favored for making industrial concentrates but requires careful control to limit degradation. For pharmaceutical and food-grade solutions, sanitation of preparation tanks and prevention of foreign matter introduction are essential due to regulatory scrutiny.
Specifications reflect intended application—pharmaceutical, food additive, animal feed, and technical/industrial grades differ in allowed impurity thresholds, physical form (crystal size distribution, flowability), water content, and assay range. Detailed specification tables are set per regulatory and customer requirements. Final release relies on the most stringent parameter among customer demands and regional compliance.
Main impurity sources in nicotinic acid manufacturing arise from incomplete oxidation, over-oxidation, or carryover of precursors such as 3-cyanopyridine, pyridine, or other pyridinecarboxylic acids. Byproduct limits are grade-dependent; food and pharma grades operate under tighter regulatory limits, while technical grades accommodate broader ranges based on end-use. The impurity profile is continuously assessed batch-to-batch, especially when changing raw materials or adjusting process conditions.
Assay, chromatic purity, residual solvent checks, and heavy metals tests follow protocols set in regional pharmacopeias, food codices, or relevant chemical standards. Potentiometric titration, HPLC, and GC-MS remain the principal methods. Selection of reference standards and calibration technique is crucial for inter-batch reproducibility and cross-lab verification.
Pyridine or 3-cyanopyridine form the backbone raw materials. Sourcing must balance traceability, impurity background, and cost stability. Regional fluctuations in pyridine supply—especially from coal tar or petro-derived sources—impact process economics and impurity load. Each incoming lot undergoes identity, purity, and suitability checks before entering the reaction stream.
The preferred industrial route oxidizes 3-cyanopyridine to nicotinic acid using air or oxygen in a catalytic aqueous system, sometimes using amorphous manganese or vanadium catalysts, depending on site-specific legacy infrastructure and emission controls. Selection considerations factor in conversion efficiency, side-reaction minimization, catalyst recyclability, and effluent management.
Key control points include oxidation temperature, oxygen partial pressure, and catalyst residence time. Continuous monitoring by inline spectrometry and reaction calorimetry provides early detection of over-oxidation or formation of non-target carboxylic acids. Downstream, multi-step crystallization and activated carbon filtration remove color and trace byproducts. Membrane filtration or ion-exchange polishing may be introduced for pharma/food lines. Batch traceability from synthesis through packaging ensures problem-solving is data-driven if specification drift occurs.
Each batch proceeds through multi-parameter QC: raw data review for process excursions, laboratory analysis for identity, assay, moisture, heavy metals, and total organic impurity content. Criteria for release align with internal SOPs and are always harmonized with customer requirements and regional regulations. Release is a cross-discipline decision involving production, QC, and regulatory teams.
Nicotinic acid offers a convertible carboxyl function and aromatic ring, supporting transformations into amide (niacinamide), esters, or various heterocyclic intermediates. These modifications feed into vitamin, pharmaceutical, or specialty chemical production lines.
Most carboxyl group derivatization occurs under mild to moderate heating with strong dehydrating coupling agents or catalytic acidic/basic promoters. Downstream processes depend on compatibility with the parent acid’s impurity background; for critical syntheses, feedstock purification or grade adjustment is routine.
Major derivatives include nicotinamide, N-alkyl esters, and heterocyclic ring modifications destined for animal supplements, dietary fortification, and pharmaceutical applications. Each derivative route applies auxiliary purification to ensure the removal of any trace parent or side-reactant incompatible with regulations or application purities.
Temperature management (cool, ambient) and isolation from moisture/laboratory vapors underpin product preservation. Light-exposed storage can promote yellowing and should be minimized. Air- and moisture-tight packaging addresses caking and hydrolysis risks for larger warehouse volumes.
Compatibility selection focuses on inert packaging: fiber drums with poly liners, HDPE barrels, or multilayer bags for bulk handling. Metallocene or non-leaching plastics prevent migration of trace contaminants that might compromise product integrity, especially for feed/food/pharma end-use. Tank or hopper re-use protocols include rigorous cleaning between lots to reduce cross-contamination risk.
Shelf life depends on packaging integrity, residual moisture, and storage environment. Degradation typically manifests as clumping, color shift, or reduction in chemical assay. Regular retesting provides assurance for inventory designated for critical or regulated applications.
Regulatory status under GHS reflects low acute toxicity but assigns warning for dust inhalation, moderate eye irritation, and possible skin irritation. Final GHS assignment depends on regional adoption and product grade.
Hazard statements highlight risks associated with handling bulk powder: avoid dust formation, direct inhalation, and eye contact. Precautionary recommendations include local exhaust ventilation, use of protective eyewear and gloves, and regular handwashing during bulk processing and packaging.
Nicotinic acid’s toxicological profile indicates low acute hazard by oral, dermal, or inhalation routes at process-level exposures. Chronic exposure limits and specific occupational guidelines depend on worker population, handling frequency, and national standards.
Workplace exposure limits, if present, track local occupational safety policies and specific application context. Industrial hygiene protocols call for periodic air monitoring and closed transfer systems for bulk dispensing to limit worker exposure to airborne particulates. First-aid and decontamination procedures exist in line with safety management system audits and material hazard assessments for the site.
Industrial-scale nicotinic acid manufacturing relies on amination of 3-cyanopyridine or oxidation of nicotine routes. Output volume varies by plant location, feedstock sources, and infrastructure capacity. European and North American factories run under continuous process systems for pharmaceutical and feed-grade, offering stable year-round supply, subject to scheduled annual maintenance. Mainland Chinese facilities generally maintain flexible batch lines, adapting rapidly to order surges but subject to raw material bottlenecks during regulatory campaigns or market disruptions. Large orders for food, feed, or technical grade can be met through centralized inventory management, with release based on both customer audits and internal SOP compliance.
As a rule, regular pharmaceutical grade (USP/EP/JP) and standard feed grade are prepared in campaign batches with lead times influenced by both batch frequency and inbound RM availability. Orders for smaller MOQs draw from finished stock or partial batch allocation; full containers or above may be scheduled directly into production if required. Lead times for specialty packaging or custom grades lengthen due to cleaning validation and segregation requirements.
Major grades including food, pharma, and industrial are offered in lined fiber drums or HDPE containers, while larger-volume feed grade is typically loaded in bulk bags with polyethylene liners, or in intermediate bulk containers on request. Custom packaging is available but triggers additional compatibility checks and regulatory confirmation, especially if direct contact or unique labelling is needed. Pharmaceutical grade cannot share lines with technical grade without validated cleaning and cross-contamination studies.
Default shipping terms are EXW, FOB, or CIF, with route and method selected according to grade, regulatory export constraints, and customer requirement. Shipments to markets such as Japan and the EU face tighter scrutiny from both shipping partners and customs in relation to traceability documentation. Payment is commonly L/C for large-volume contracts, T/T for ongoing supply, and advance remittance for trial or specialty batches. All terms must match contractual framework, including audit rights and recall logistics.
Raw material sourcing dominates cost structure. The upstream pyridine market swings widely based on crude oil derivatives, energy cost spikes, and plant turnarounds. During periods of regulatory enforcement in China or export restrictions on intermediates, supply for 3-cyanopyridine tightens, sending price upward. In-house analytics track feedstock index movements, energy tariffs, and historical supply chain interruptions to flag S&OP adjustments in batch cost calculation.
Batch-to-batch pricing also reflects compliance-driven cleaning, additional GMP documentation, and segregation provisions. This is especially visible on high-purity and parenteral grades due to market-mandated analytical release and impurity profiling. Fluctuations spike if major global suppliers undergo unplanned shutdowns or if new regional regulatory standards force rapid plant upgrades.
Cost separation between technical, feed, food, and pharma grades originates from initial purification, intermediate holding, and release analytics. Feed grade supports higher impurity bands; food grade typically shows stricter organic contaminant limits. Pharmaceutical grades include expanded testing—endotoxin, residual solvents, and elemental impurity panels. Container certification for direct food or injectable interface can drive up per-unit cost, requiring third-party validation or serialized tracking.
Price differences for the same grade can also result from tailored particle size, certificate authentication, or additional stability data requested by the customer. Regulatory certifications such as FSSC, GMP, or Kosher/Halal are routinely audited and add compliance overhead.
China supplies more than half of global nicotinic acid volume, with major export flows to North America, Europe, and Southeast Asia. The global animal nutrition and functional food sectors continue to expand uptake, though pharmaceutical sector growth is largely stable due to generic market maturity. Major producers operate with capacity buffers to handle both cyclical order patterns and unplanned local demand surges driven by animal disease outbreaks or food fortification mandates.
| Region | Market Drivers | Import/Export Dynamics |
|---|---|---|
| US | Strong animal feed market, pharma demand steady | Relies on both domestic and Asian imports; FDA listing required for high-purity grade |
| EU | Feed, fortification, food additive sectors; compliance is high cost | Germany, France key importers, REACH influences sourcing |
| JP | Food additives, specialty pharma; quality focus | Preference for domestic or certified suppliers; JDM documentation needed |
| IN | Feed growth, pharma sector is expanding | Imports from China and EU; increasing local production |
| CN | World’s largest producer and exporter | Exports globally, faces regulatory interventions on emissions and effluent controls |
Pricing into 2026 most likely follows the trajectory of raw material price cycles and energy costs. Installation of new emission controls and increased scrutiny of waste management in China may tighten supply temporarily during plant retrofits. Additional regulatory requirements in the EU and North America will favor compliant manufacturers but introduce higher compliance costs. Feed grade pricing will see moderate growth tied to livestock and aquaculture market resilience. Pharma and food grades have potential for sharper increases if input costs or compliance burdens rise unexpectedly. Market data and forecast assumptions use industry purchasing data, regulatory announcements, and major producer reported results.
Market supply and pricing trends derive from producer consortia reports, published customs data, regulatory filings, and proprietary end use demand mapping. Interpretations align with major international chemical industry analyses and in-house S&OP projections.
Several new players have announced investments in pyridine intermediate capacity in Asia since 2023. Regional power grid reforms and stricter emissions management campaigns in major Chinese chemical provinces have triggered temporary shutdowns and output curtailments. In Europe, the push for animal traceability and fortified foods supports stable demand amid rising quality audit requirements.
Recent framework changes in EU (REACH Annex expansion) and updated pharmacopoeial monographs for nicotinic acid in several regions have required batch record revision and process verification. The US FDA continues to reinforce site audit requirements for dietary ingredient producers. GMP and HACCP audit frequency has increased at major export-facing manufacturing sites.
Manufacturers facing environmental and regulatory criteria adopt phase-by-phase process validation, upstream supplier qualification programs, and contingency inventory reserves. In response to supply volatility, dual-sourcing and localized inventory strategies have become more frequent, especially among pharmaceutical grade buyers. In terms of compliance, third-party accredited labs and digital batch release tracing platforms support both customer assurance and recall readiness.
Nicotinic acid plays multiple roles across industrial sectors. Common segments include the feed and food additive industry, API/pharmaceutical manufacturing, cosmetics formulation, and certain electronic and chemical synthesis fields. Feed and food applications require control over impurities—such as heavy metals and residual solvents—though the target impurity profile depends on intended use and local regulatory requirements. In pharma-grade production, batch reproducibility, validated traceability, and minimization of genotoxic impurities carry decisive weight. Cosmetic and electronic uses, on the other hand, may prioritize particle size or dispersibility over biologic safety.
| Industry | Target Grade(s) | Main Technical Considerations |
|---|---|---|
| Feed & Premix | Feed/Technical Grade | Animal safety, presence of niche contaminants, flow performance in mixing lines, compliance with regional limits (e.g., EU, US) |
| Food & Dietary Supplements | Food Grade, USP/EP | Low impurity profile, allergen-free certification, particle morphology, full supplier traceability, Halal/Kosher/Non-GMO if required |
| Pharmaceutical & API | USP/EP, Pharma Grade | Consistent release profile, validated manufacturing and QC records, stringent absence of specific nitrosamines and heavy metals, regulatory documentation for DMF/CEP as applicable |
| Cosmetic | Cosmetic or Food Grade | Particle size, dispersibility, odor, absence of restricted substances (IECIC/REACH regulations), stability data |
| Electronics & Synthesis | Technical/Industrial Grade | Process compatibility, solubility profile, impurity control specific to downstream process, sometimes tailored to customer’s process |
Key parameters impacting each application include grade-defining impurities (such as 2-methylpyridine in technical grade, or residual solvents in pharma/food grade) and physical properties like particle size or flowability. Heavy metals, microbial limits, and batch homogeneity often weigh most for regulated end uses. Producers must track micro-impurity sources in raw materials and control critical points in synthesis and purification, as carry-over or cross-contamination can trigger downstream compliance issues.
Internal teams should clarify the end use, whether in premix feed, nutrition, pharmaceutical intermediates, or chemical synthesis. Production will match the requested application with our existing grade map or suggest fit-to-purpose release criteria. Most failures to qualify a grade stem from misalignment at this stage.
Regulations define acceptance criteria: for pharmaceutical clients, monographs such as USP, EP, or ChP may apply, with close oversight from QA. Food and feed customers reference local authorities or Codex—traceability, allergen status, and permissible contaminants are reviewed before accepting lots. For cosmetics and industrial, reach and local chemical registrations come into play.
Product purity is not a one-size-fits-all property. Some feed applications allow higher impurity thresholds than food or pharmaceutical ones; in API settings, purification targets lower micro-toxicant levels, lower bioburden, and reduced levels of process-related impurities. Our QC lab will only release material if the batch meets pre-agreed standards. Tightening purity requirements often impacts process economics and may prompt a shift to alternative raw materials or additional purification steps.
Production planning balances customer volume forecasts with batch size. Feed and technical grades deliver on cost, with larger lot sizes reducing per-kg expense, if purity demands allow. Pharma and high-purity food grades run at smaller batch volumes, reflecting higher labor and analytical costs, plus greater regulatory overhead.
Procurement or R&D teams should validate our sample material with real-use trials. Our technical service can assist with compatibility, handling, and stability advice. Samples come with full COA and batch records for trace review. Feedback from validation blends into our continuous improvement and supports final procurement decision-making.
Every grade of nicotinic acid involves distinct raw material selection logic, driven by intended end-use tolerance on impurity classes. In pharma-linked lines, operators map out potential nitrosamine sources from upstream chemicals and prioritize campaign production to avoid cross-contamination. Each process route—oxidation, amination, or catalytic transformations—generates its own impurity profile and must be selected to balance yield, safety, and regulatory compliance. Purification often layers recrystallization with targeted filtration to pin down final purity.
Critical points in QC focus on verifying batch-to-batch consistency of appearance, solubility, and release criteria. In-process controls address process drift, contamination risks, and conversion yield. QC release only clears product that meets both generic compliance and any specific customer specification. All releases are subject to our periodic review and corrective action system.
Client feedback shapes process upgrades. Applications that demand tighter microbiological limits or niche certifications—such as non-GMO—trigger sourcing and process adaptations on our end. Downstream handling guidance will depend on grade: free-flowing feed powders may require anti-caking agents, pharma requires validated secondary packaging, and technical grades may be shipped in larger bulk for further processing.
Manufacturing nicotinic acid at industrial scale requires robust quality management protocols to minimize process deviations and batch variation. Our operations maintain compliance with internationally recognized quality management systems to address traceability, auditability, and batch history across the full production chain. Audit evidence is retained according to standard retention cycles to support customer or regulatory inspections. Certification coverage and process scope may vary depending on the intended end-use region or downstream market. The application area, such as feed, food, or industrial grade, will often dictate which quality management certification frameworks are applicable.
Certifying product batches to meet various regulatory or voluntary standards forms a critical part of the release process, especially for pharmaceutical and food-related applications. Certificates of Analysis reflect test outcomes from finished product lots, covering parameters tied to specifications agreed with customers. For higher-purity or food/pharmaceutical grades, third-party audits may validate compliance to specific monographs or regional market regulations. Documentation supporting these certifications is available for audit upon request and can include product registration dossiers for export or tenders, subject to applicable regulatory confidentiality protections.
Document provision follows the structure needed for regulatory filing or customer qualification requirements. Technical documentation includes batch-specific quality reports with test data—these typically detail assay, impurity panel, appearance, identification, moisture, and other critical parameters suited to the grade in question. Extended documentation such as supply chain transparency statements or process flow diagrams may be provided as justified by end-use or regulatory context. Retention of production documentation covers a period aligning with market norms, notably where product traceability may be required for recall or investigation scenarios. Customers can receive supporting documents, including quality agreements, if dictated by their supply chain management systems or third-party audit requests.
Nicotinic acid production relies on a continuous process with a focus on raw material sourcing stability and equipment uptime. Ensuring continuous availability for customers comes down to sustained process yield, feedstock quality consistency, and predictive maintenance plans to minimize unscheduled downtimes. Customers seeking stable or long-term supply often prefer advance purchase cooperation agreements. These plans allow for dynamic adjustment of shipment schedules and minimum stock levels, responsive to real fluctuations in downstream demand or inventory requirements.
Core production capacity is determined by the reaction route, equipment design, and utility infrastructure. Excess capacity is managed by controlling campaign scheduling or by allocating dedicated production slots to strategic customers with high-volume or critical demand. Batch size, grade selection, and impurity control impact available output, especially as higher-purity or application-critical grades may require production under specific campaign conditions to avoid cross-contamination. Discussions around minimum batch size or periodicity of supply are conducted directly with downstream users to ensure output aligns with storage capability and throughput.
Sample provision supports customer qualification and is handled in direct coordination with technical and quality control teams. Standard sample volumes and packaging formats must match the end-use application and the customer’s handling practices. Sample dispatch is accompanied by batch-specific analytical reports, with test coverage and documentation matching the final commercial supply. Feedback from customer sample evaluation is collected to adjust production or specification points as necessary before transitioning to commercial volumes.
Business cooperation modes offer a range of options from spot contracts to rolling annual agreements. Open allocation of campaign or batch quantities is possible for users facing volatile demand or regulatory lead times. Shared forecast mechanisms, consignment stock models, and just-in-time call-off plans can be arranged for qualified partners. Quality non-conformance or supply disruption protocols are jointly developed, ensuring rapid rectification based on previously defined quality agreements. Logistics, packaging, and customized mark or documentation requests are managed according to mutually agreed timelines and compliance requirements relevant to the customer’s regulatory landscape or operational complexity.
Nicotinic acid research focuses on expanding efficiency in pharmaceutical synthesis, lowering waste in production, and improving product stability for demanding downstream processing. Current laboratory work often centers on optimizing raw material input to minimize nitrogen-oxide byproducts, a concern both for regulatory compliance and plant performance. Fermentation-based processes attract R&D attention due to their potential to replace chemical routes in locations with access to competitive bio-feedstocks, provided process yield and impurity profiles can match chemical synthesis standards.
Traditional applications in human and animal nutrition continue, but industrial users increasingly request high-purity grades for electronics, catalyst precursors, and specialty polymers. Water-soluble vitamin tablets, feed premixes, and pharmaceutical intermediates set different impurity limits and demand consistent color and solubility behaviors. Functional coatings and corrosion inhibitors drive demand for tighter control on reducing metal ion content.
Achieving batch-to-batch consistency at scale often meets bottlenecks in solvent recovery efficiency, precise pH monitoring, and heat transfer management during nitration and hydrogenation. Sodium and chloride residue levels must remain below customer-defined thresholds, especially for injectable or food-grade material. Technical breakthroughs in continuous purification and membrane-based separation help manage organic and inorganic impurity carryover, but commercial deployment still requires process adaptation and long-term validation in high-throughput lines.
Global demand is expected to grow steadily, led by regulatory enforcement on nutritional fortification and extended use in veterinary feed. Supply chains favor manufacturers with vertically integrated upstream supply and documented in-country quality audit records. Market risk factors remain raw material price volatility and periodic tightening of export approvals for related feedstocks in select regions.
Continuous investment in process intensification shifts the balance between batch and continuous-flow operations. Manufacturers with digitally monitored reaction control platforms can more readily ensure real-time tracking of critical parameters. Modular reactor designs enable product-grade switching with reduced downtime and support emerging demand for high-grade electronic and pharmaceutical intermediates.
Internal projects prioritize lowering overall water use and capturing volatile emission at the reactor stage. Partnering with technology licensors to adapt catalytic hydrogenation routes lessens reliance on stoichiometric reducing agents. Progress is measured by life-cycle analysis outcomes, especially for product destined for regulated markets, and must be demonstrated by annual audit documentation for buyers with internal ESG screening.
Our technical team responds directly to client requests regarding grade selection, compatibility with downstream blending, or regulatory documentation. We interpret analytical results and assist with root-cause investigations if off-grade issues arise during initial product switching or new process validation.
Optimization services adjust granule size distribution or micro-screening levels to ensure fit with client granulation or tableting units. For users requiring customized impurity profiles, joint-lab trials can be arranged to support specific formulation goals. Data on solubility, dispersibility, or trace element content are available for review with supply chain partners to minimize end-user re-testing.
We maintain product traceability based on batch coding, linked to in-house retention samples for at least one year post-delivery. Complaints or deviations are tracked in our QMS with formal CAPA response. Ongoing technical bulletins communicate process adjustments or regulatory status changes relevant to supplied product grades. All documentation, COAs, and supporting test records follow original batch criteria and customer-specific quality agreements.
Production lines at our facility handle nicotinic acid synthesis from raw stage through to final purification and drying. Each step is strictly managed to safeguard batch consistency, which is essential for downstream users relying on reproducible chemical behavior. Our process engineers constantly review reaction yields and monitor key parameters on real-time systems. This approach allows us to quickly identify and minimize variation, keeping supply predictable for industrial operations. We produce nicotinic acid in volumes suitable for large-scale blends, premixes, and direct industrial applications.
Our customers draw on nicotinic acid’s performance across several markets. In animal nutrition, it acts as a vital source of vitamin B3, delivering dependable results batch after batch. Food fortification relies on stable product grades to meet nutritional targets and maintain regulatory compliance. Our pharmaceutical clients need reproducible purity profiles to formulate solid dose supplements. Chemical manufacturers use nicotinic acid as an intermediate, appreciating its chemical integrity for further synthesis and functionalization.
Manufacturers in regulated sectors cannot afford product variability. For this reason, our QA/QC laboratory runs each lot through identification, assay, and specific impurity analysis. Methods conform to authoritative compendial standards, with additional in-house controls built from years of process experience. Shelf-life tracking under controlled storage highlights stability over time. Each batch leaves the site with supporting documentation and full traceability to starting materials.
We handle both high-volume export shipments and tailored smaller deliveries through various packaging formats. From fiber drums for bulk delivery to double-layer lined sacks designed to protect against humidity and contamination, packaging choices address logistics requirements and regulatory needs. Multi-site storage and established delivery channels allow for reliable just-in-time replenishment, even amid changing demand cycles.
Process engineers in customer plants often face questions during qualification or scaleup. Our technical staff understand the practical realities of integrating nicotinic acid into different process trains, whether for premix blending, compounding, or feed formulation. We provide documentation support for compliance needs and work directly with formulation chemists to troubleshoot application issues, process tolerances, and specification verification.
Procurement and sourcing teams depend on our predictable lead times and uncrowded supply arrangements. Direct manufacturer control cuts layers from the supply chain and allows for straightforward dialogue about production status and upcoming needs. Cost predictability results from our investment in process efficiency and stable input sourcing. For supply chain partners and end manufacturers, this translates into fewer surprises and more planning certainty in a tightly regulated industry landscape.
At our facility, production of nicotinic acid always starts with full attention to both raw material quality and controlled synthesis parameters. Pharmaceutical applications demand rigorous standards. Low impurity levels and high lot consistency do not occur by accident; they require disciplined process control from first reaction charge through to final drying and packaging.
High assay purity sits at the center of our workflow. For pharma use, regulatory bodies and drug master file submissions require a consistent, well-documented process. Purity, for nicotinic acid, involves the actual measured content of the main compound in a batch, usually calculated using validated analytical methods such as HPLC or titration.
Assay specification is not simply a number on a certificate. In real-world pharmaceutical manufacturing, each microgram of impurity can affect a finished product’s profile. Our process delivers typical assay values of not less than 99.5%. Meeting this level means byproducts, nitrosamines, and trace residual solvents fall within tough regulatory thresholds.
Each batch starts with trusted raw materials, carefully sourced and qualified. Our synthesis steps minimize side-reactions, and in-process checks spot any drift early. Workers on the floor understand how even a few tenths of a percent off-target can have consequences down the line.
QC analysts use validated methods to verify purity. Common reference standards come directly from recognized pharmacopoeias. Each lot must meet or exceed specifications—greater than 99.5%, frequently touching 99.7% or higher based on recent analytical runs. Only those lots clearing microbial, heavy metal, and impurity criteria carry our release approval.
Our customers include major finished dosage manufacturers as well as CMO partners, who rely on us for technical files and robust change control. High purity reduces the workload in further compounding, improves compatibility with other actives and excipients, and assures regulatory inspections move smoothly.
Should a client require even narrower specifications, our engineers work closely with their team to tighten process controls. Intensive process documentation, batch traceability, and audit support are all standard from our technical side. We can offer supporting data packages on impurity profiles and stability information as part of regulatory submissions.
We invest in plant upgrades and automation to further reduce the risk of contamination. As market pressures shift—whether from evolving USP, EP, or JP monographs or heightened regulatory scrutiny—our technical team keeps our documentation and process capability ahead of the curve. Batch-to-batch reproducibility comes from decades of continuous operation and feedback with world-class formulation partners.
Our assay standards match or surpass the requirements found in most global pharmacopoeias for oral, topical, and parenteral applications. Pharmaceutical customers benefit from supply reliability, regulatory-ready paperwork, and the flexibility that comes from dealing directly with the plant that makes their API.
We produce nicotinic acid in facilities engineered for consistent, high-volume output, because our direct customers typically need reliable batch-to-batch performance. Our manufacturing runs reflect this scale. The minimum order quantity (MOQ) for bulk procurement results from a balance of manufacturing costs, raw material logistics, handling protocols, and packaging efficiency.
MOQ for nicotinic acid usually starts around the level of a full pallet, equivalent to several hundred kilograms. A smaller quantity increases the per-unit production and operational costs, which runs counter to established industrial process economics and compliance standards. We calibrate palletization and drum packaging for both chemical stability and transport safeguards, which gives buyers in bulk predictable costs and minimizes goods damage. The MOQ is not arbitrary—below a certain threshold, labor and energy outstrip the value of the product itself. We’ve found that keeping bulk orders above this MOQ aligns with both consistency and value for our end-users. For custom packaging or highly specialized grades, adjustments do occur, but the base MOQ remains the starting point for commercial discussion.
Direct-from-factory lead times reflect actual production schedules and existing stock levels, rather than intermediary warehousing or speculative inventory. For bulk nicotinic acid, our standard lead time lands between two to four weeks under normal operational conditions. Fluctuations crop up from raw material deliveries, maintenance turnarounds, and shipping requirements, but we schedule runs based on precise demand forecasts, not guesswork.
Emergency orders often surface when end-users face unexpected spikes. We have developed fast-track capabilities for such cases, subject to plant capacity and regulatory clearance. With consistent demand planning from customers, we minimize costly idle periods or excess stock situations. Changes in government regulations—or shifts in permitted excipient limits—may shift priorities in the queue, so we keep ongoing communication with buyers who need continuity of supply for food fortification, pharma, and feed applications.
Quality doesn’t come from paperwork—it starts on the factory floor and follows every batch through analytical testing and documented lot traceability. Every bulk shipment leaves with robust QC documents, batch analyses, and, if requested, third-party testing confirmations. Some customers ask for specialized particle size distributions or purity grades. We can engineer these adjustments efficiently, but rare-sku lots may require longer lead times than standard grades due to validation and change control.
Customers with strict cGMP or documentation requirements work directly with our regulatory affairs and technical service teams throughout the procurement cycle. We provide full transparency for every batch, supporting end-use compliance in regulated industries without delay. For recurring buyers, long-term supply contracts reduce both lead time variability and the risk of disruption.
Bulk buyers depend on factory-direct engagement for stable pricing, prompt logistics, and responsiveness to specification changes. We invest in plant modernization, automated quality controls, and raw material security, which sustain order fulfillment even during peak demand. Industry trends—such as increased use in fortification and biopharma—drive us to scale up both capacity and flexibility. For technical questions and pre-purchase samples, our technical team supports industrial R&D and trials, ensuring that every ton delivered matches critical process needs.
Nicotinic acid always generates regulatory questions, especially with customers shipping our material across different borders. As a direct manufacturer, we face these inquiries daily—not just from importers but also from regulatory authorities, freight forwarders, and auditors. Regulatory compliance for nicotinic acid often blends chemistry knowledge with practical logistics and, each year, the documentation standards get more comprehensive.
Nicotinic acid (also known as niacin or vitamin B3) serves countless end uses, from feed-grade to pharmaceutical applications. Its chemical classification, regulatory status, and purity directly determine what paperwork accompanies each batch. In most jurisdictions, this product is not classified as a hazardous material, which rules out requirements like Dangerous Goods certificates or ADR/RID/IMDG codes. Yet, for international movement, customs officers rarely take our word alone. They request the full documentation, sometimes even before cargo leaves our loading dock.
At our facility, each outgoing shipment includes a batch-specific Certificate of Analysis, signed and stamped by our QC manager. These certificates back up our manufacturing process and guarantee the specification parameters match international codices such as the USP, BP, or FCC listings. Documents like the SDS (Safety Data Sheet) remain non-negotiable. Customers in North America, Europe, and parts of Asia demand these safety sheets in a standard 16-section format, updated every three years or with any hazard classification change. Our technical team reviews all chemical hazard communication and ensures full completeness, covering not just composition and handling hazards, but spill, exposure, and waste management sections as well.
The import landscape dictates additional needs. For instance, our customers shipping to the EU or US often require REACH or TSCA compliance statements. We maintain updated documentation confirming our product’s inclusion in the appropriate inventories. Inspections at the destination sometimes request a clear declaration of origin, along with an invoice and packing list matching the labels and markings on the external packaging. Each drum or bag exiting our plant includes batch numbers, manufacturing dates, and traceability codes—our approach reduces confusion and translates to fewer inspection delays.
Pharmaceutical and food industry buyers across South America, Africa, and Southeast Asia occasionally require Halal or Kosher certifications. Many buyers ask for GMP or ISO documentation showing that our factory adheres to the needed best practices for safety, cleanliness, and consistency. For key pharmaceutical classes, our dossiers often get reviewed under local authority guidance (ANVISA, SFDA, MFDS, etc.), so we manage detailed regulatory submissions covering stability, impurity profiles, and process validation.
International standards change frequently. Our regulatory affairs group monitors notifications from agencies like ECHA, FDA, and local product regulators, making adjustments to literature or labels as soon as new mandates are issued. We also coordinate with freight forwarders to guarantee packaging meets required labeling, from GHS pictograms to transportation instructions in local languages where necessary. Some clients require pre-shipment inspection or even in-person product verification—our team coordinates this from start to finish, minimizing risk of customs hold-ups and ensuring transparent, traceable exports. This focus on process integrity supports uninterrupted deliveries and long-term business trust in every market we serve.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales7@bouling-chem.com, +8615371019725 or WhatsApp: +8615371019725
